1. Academic Validation
  2. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1

Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1

  • Bioorg Med Chem Lett. 2004 Jul 5;14(13):3389-95. doi: 10.1016/j.bmcl.2004.04.083.
Lawrence A Reiter 1 Ralph P Robinson Kim F McClure Christopher S Jones Matthew R Reese Peter G Mitchell Ivan G Otterness Marcia L Bliven Jennifer Liras Santo R Cortina Kathleen M Donahue James D Eskra Richard J Griffiths Mary E Lame Arturo Lopez-Anaya Gary J Martinelli Shunda M McGahee Sue A Yocum Lori L Lopresti-Morrow Lisa M Tobiassen Marcie L Vaughn-Bowser
Affiliations

Affiliation

  • 1 Pfizer Global Research & Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA. reiterla@groton.pfizer.com
Abstract

The SAR of a series of sterically hindered sulfonamide hydroxamic acids with relatively large P1' groups is described. The compounds typically spare MMP-1 while being potent inhibitors of MMP-13. The metabolically more stable compounds in the series contain either a monocyclic or bicyclic pyran ring adjacent to the hydroxamate group. Despite the sparing of MMP-1, pre-clinical and clinical studies revealed that fibrosis in rats and MSS in humans is still produced.

Figures
Products